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Abstract 
The lagunamides are group of natural products derived from cyanobacterium. 
Lagunamides A, B, and C have shown impressive cytoxicity towards a panel of cancer and malarial 
cell lines. Each of the lagunamide family members share structural similarities within their 
polypeptide backbone, but the polyketide units with A/B differ from C by an additional methylene 
insertion. The total synthesis of lagunamide A and an analog of lagunamide B have been reported 
by Dai and Pal’s groups, respectively. The synthesis of lagunamide A was completed first by Dai 
and proved that the original structural elucidation was incorrect. With this inaccurate 
stereochemical assignment, it was suspected that this inaccuracy also appeared in the structural 
elucidation of Lagunamide B that was completed by Pal. It is alleged that these inaccuracies have 
occurred in the stereochemical assignments of the isolated structure of lagunamide C.  
In addition to the stereochemical inaccuracies, a new synthetic route is necessary to 
synthesize lagunamide C. The structures of lagunamides A and C are nearly identical, except for 
the addition of one carbon in the polyketide portion of lagunamide C. This additional carbon 
disallows the use of same synthetic methods applied on lagunamide A to be employed on the 
synthesis of the polyketide portion of lagunamide C. 
This work will discuss a modular approach towards the synthesis of lagunamide C. Model 
systems were employed to test the validity and success of the proposed route. Key steps of the 
proposed synthetic route include a titanium mediated mixed aldol reaction, cyclopropanation, and 
Charette cyclopropane ring-opening. The current synthetic route is shown to be scalable and 
possessing optimizable transformations. These steps have proven to be successful with the model 
systems and have laid the groundwork for the synthesis of the target compound, lagunamide C.
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Chapter 1 - Introduction to Natural Products  
 1.0 Introduction  
Humans have been taking advantage of nature’s organisms for millennia. 1 Tea has been 
used in Asian civilizations for over 4,000 years as a social beverage, remedy for ailments, and 
carries ceremonial significance. 2 The aloe vera plant has been used all over the world to sooth 
burns and skin irritation and to treat constipation. 3 South American cultures use coca leaves to 
soothe toothaches, headaches, and altitude sickness. 4 Honey is used as a natural sweetener, 
antibiotic, and as treatment for the common cold. 5 These natural products are derived from all 
walks of life including plants, animals, insects, and microbes. While seemingly ordinary, these 
resources provide an arsenal of compounds for treating disease. 
These natural products, equipped with unmatched structural and chemical biodiversity, 
have been evolutionarily optimized has secondary metabolites for the host organism. 6 Secondary 
metabolites are compounds that are not directly involved with the growth, reproduction, or 
development of an organism, and are often involved with developments such as unique defense 
mechanisms, sexual hormones, and differentiation. 6  An example of secondary metabolites can be 
found in some species of cold water fish. These organisms contain “anti-freeze” proteins that 
enable them to thrive in extremely cold conditions by preventing the water in cells from freezing 
and bursting. 7 
Scientists have found secondary metabolites to contain medicinal, cosmetic, and nutritional 
properties of interest for human use. Common examples of secondary metabolites include Botox, 
recognized for its ability to treat at least 50 types of smooth muscle conditions, the analgesic 
aspirin, and the primary drug for treating breast and ovarian cancers, Taxol. 
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 1.0.1 Botox 
Clostrium botulinum is the gram-positive food-borne bacteria infamous for botulism and 
is currently one of the deadliest neurotoxins on earth with IC50 values of 1-2 μg/kg in humans. 8 
These effects are caused by seven neurotoxins, A-H, produced by the bacteria. The toxin works by 
binding to recognition sites in muscle cells and decreases the release of acetylcholine, thereby 
causing a temporary neuromuscular blockage. 8, 9 Arresting the release of acetylcholine prevents 
the muscles from contracting, and becomes deadly when respiratory and cardiac muscles are 
paralyzed. 10 Botulinum toxin A, shown in Figure 1, is the most potent form and is currently the 
only form of the toxin commercially available for pharmaceutical use. 9, 10 
 
 
 
 
 
Originally, it was thought that botulinum toxin was spread through the consumption of 
specific foods, such green beans; however, in the early 1900’s, it was found that the poison was a 
result of improper food preservation methods. 8 Medicinal use of botulinum toxin was not 
employed until the mid-1970’s after a study completed by an ophthalmologic surgeon, Alan B. 
Scott, found that if picograms of botulinum toxin was administered to a subject, the toxin remained 
relatively localized to the injection site, and therefore produced localized paralysis. 8 This ground 
breaking discovery lead to treating a variety of conditions including strabismus and hyperactive 
sweating.  
Figure 1 Quaternary Structure of Botulinum Toxin A11 
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  Botulinum toxin A is prepared for clinical use by isolating the toxin from C. botulinum 
cultures. It is then diluted with albumin, bottled, and lyophilized. 9 Botulinum toxin A has been 
employed to treating several conditions including focal dystonias, smooth muscle hyperactive 
disorders, overactive bladder disorders, and cerebral palsy. 8 In the early 2000’s, the toxin was 
FDA approved for the prevention and treatment for facial wrinkles induced by aging. This method 
of administering the toxin is now commonly known as Botox. 8, 9 
 1.0.2 Aspirin 
 Another well-known natural product is the household analgesic aspirin - one of the most 
common substances used in modern medicine. This compound, derived from willow tree bark, has 
been used to relieve pain for thousands of years.12 The first documented use dates back 4000 years 
by the Sumerians.12, 13 Historical figures, including Hippocrates and Dioscorides, attribute pain 
relieving and anti-inflammatory properties to orally administered willow tree bark.14 
While the medicinal benefits of willow tree bark were recognized, the drug was first 
chemically investigated in the early 19th century. Powder from willow tree bark was administered 
to patients in the first clinical studies completed by Reverend Edward Stone.12 Over time, patients 
found that using the drug was an effective pain reliever, but they experienced severe pain and 
irritation towards mucus membranes. The active chemical derived directly from willow tree bark, 
salicin (1), as shown in Scheme 1, was isolated by Johann Buchner in 1828, and the pure crystalline 
form of salicin was isolated by Henri Leroux in 1829.12, 14 Large scale production of salicylic acid 
(2) began in the late 1800’s and became available for medicinal use.14  
While many patients experienced pain relief from salicylic acid, it came at a cost. Regular 
use of salicylic acid left patients with painful gastrointestinal irritation and damage. It was found 
that the body metabolizes salicin into salicylic acid, the chemical responsible for the mucosal 
4 
membrane irritation, thus limiting its beneficial effects.14 A new drug with less severe side effects 
was necessary. 
Scheme 1 Conversion of salicin to salicylic acid; acetylation of salicylic acid 
 Felix Hoffman was given the task of finding a drug that served as a pain reliever, anti-
inflammatory, and fever reducer, but did not cause adverse side effects.12 The solution was found 
via the acetylation of salicylic acid. This acetylated form of the drug still served as a pain reliever, 
but did not have the adverse side effects that were produced by salicylic acid alone. When 
administered, acetylated salicylic acid (3) is metabolized back into salicylic acid and used by the 
body as shown in Scheme 1.14 In 1899, this new acetylated drug was entitled “Aspirin” by The 
Bayer Company, and became available without a prescription in 1915.14 Over 100 years later, this 
naturally-derived drug is still used as a pain reliever, anti-inflammatory agent, and blood thinner 
without inducing adverse side effects.  
 1.0.3 Taxol 
 Like aspirin, paclitaxel (also known as Taxol, illustrated in Figure 2, is a natural product 
derived from tree bark.16 Taxol (4) was isolated from the yew tree, T. brevifola, by the US National 
Institute of Health in 1966 during a plant screening program and was later found to be potent IC50 
values towards a variety of cancer cell lines including HeLa (cervical, 2.6 nM), A549 (lung, 4.1 
nM), U373 (Grade III astrocytoma, 4.2 nM), MCF-7 (breast, 2.5 nM), HT-29 (colon, 2.8 nM), 
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OVG-1 (ovarian, 4.0 nM), PC-Sh (pancreatic, 7.5 nM), and and PC-Zr (pancreatic, 4.0 nM).15 The 
structure was elucidated in 1977 and clinical trials were approved for treating cervical cancer in 
1993, causing a great demand for this compound.16   
 
Figure 2 Structure of Taxol 
As a viable treatment for several types of cancer, Taxol was vital, but obtaining it proved 
challenging.17 While the compound can be extracted from the yew tree, the overall yield from 
extraction is very low, 0.02% overall yield.17 Obtaining a gram of Taxol would require the bark of 
approximately three yew trees.17 This method also posed a problem for the survival of the yew 
tree, as the tree dies following the harvest of the bark. The cost of formulating Taxol directly from 
the bark was very high, costing ten times the allotted budget of the screening project.17 A more 
efficient method of obtaining this valuable compound was significantly necessary in order to 
produce the drug on a larger scale to satisfy high demand of the compound.  
Several methods were tested to obtain mass quantities of Taxol, including farming, cell 
culture, semi-synthesis and total synthesis.16 The semi-synthesis of Taxol, shown in Scheme 2, 
involved extracting starting material, 10-deacetylbaccatin III, from a shrub, T. baccata, and then, 
via synthetic manipulations, acquire the desired compound.17, 18 Ultimately, Taxol would need to 
be synthesized in order to obtain enough of the compound to be clinically administered to cancer 
patients. 
6 
 
Scheme 2 Semi-synthesis of Taxol 
The total synthesis of Taxol was achieved in two years by Nicolau et. al in 1995, nearly 
thirty years after its original discovery.16 It was important to have a relatively short, manipulative, 
synthetic route that not only produced Taxol, but analogs of the compound throughout the process. 
The synthesis took over 40 steps and involved key reactions including a Shapiro Reaction, 
McMurry Coupling, and Sharpless Epoxidation with an overall yield of less than 0.1 %.16 The total 
synthesis of Taxol has allowed for obtaining enough of the compound to use in medicine without 
completely depleting the natural source. 
 1.1 Total synthesis 
Friedrich Wöhler, a German chemist, is attributed for synthesizing the first organic 
compound, urea (7), as shown in Scheme 3, through the heating of ammonium cyanate (6).19 His 
discovery refuted the “vitalism hypothesis” thus proving that organic compounds can be 
synthesized from inorganic chemicals.20  
 
Scheme 3 Conversion of ammonium cyanate to urea via Wohler Synthesis 
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This method of generating materials, termed total synthesis, has exploded, resulting in the 
synthesis of thousands of compounds ranging across various disciplines in society.20 Dyes, 
polymers, cosmetics, textiles, pesticides, and pharmaceuticals are a small handful of products 
made available by total synthesis.20  
The Wohler Synthesis of urea initiated the synthesis of thousands of compounds, including 
secondary metabolites with medicinal properties such as aspirin, and Taxol.20 With the exception 
of botulinum toxin A, extracting the compounds from their natural sources is neither economical, 
nor ecologically feasible.  Salicin (1) extracted directly from the willow tree must first be formed 
into salicylic acid and then acetylated into its most usable form. The yew tree, T. brevifola, is slow 
growing, relatively rare, and considered an endangered species.17 In order to obtain enough of the 
respective compounds from their natural sources, their natural source would be completely 
depleted and dramatically increase the cost of the drug. Issues like this can be resolved through 
total synthesis. This process allows scientists to obtain these compounds without depleting their 
natural sources and allows for stereochemical modifications of the compounds for medicinal use.  
This method of production is not without caveats, as it is often a lengthy, synthetically 
challenging, and expensive process.20 Complicated structures often require more steps with more 
care placed towards facial selectivity. However, synthesizing complex structures can have 
beneficial biological and chemical implications that make the process rewarding.20 For example, 
the total synthesis of Taxol was revolutionary in the field of synthetic chemistry, and is used to 
help treat several types of cancer. Conversely, producing Taxol on a large scale via total synthesis 
is problematic. 
Total synthesis can lead the scientific community to question the necessity of this method 
as it is often an expensive and lengthy process that is not necessarily feasible towards mass 
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production. For instance, a total synthesis for aspirin and Taxol, among thousands of other 
medicinally important compounds, have been completed, but, are not necessarily the way in which 
mass quantities of the drug are obtained. Taxol is currently produced semi-synthetically. An 
important aspect of total synthesis is that it allows for the formation of non-natural derivatives of 
compounds that could provide new drug leads. 1  
 1.2 Natural products and cancer 
 Cancer is one of the most notorious diseases known to mankind and is the second leading 
cause of death in the United States.21 It is estimated that more than 600,000 people will die and 
over 1.6 million new cases of cancer will be diagnosed in 2017 alone.21 Apart from practicing 
preventative health measures, such as eating a healthy diet and exercising, new drug leads are 
necessary to fight this disease. Discovering and synthesizing new natural products may be key to 
fighting cancer. 
 Since the 1940’s, over 75% of anticancer drugs have been inspired by natural products 
found in both terrestrial and marine sources.23 Earth’s oceans have been a leading source for natural 
products and recent advances in technology allow for scientists to explore areas of the ocean once 
deemed “unreachable”. Since 2012, over 1100 new marine natural products have been documented 
and thirteen of these are currently undergoing the final stages of clinical trials.22, 23 Nine have been 
approved for medicinal use and include cytarabine (Ara-C), trabectedin (8), halichondrin B, and 
auristatin E.23 
These compounds are derived from a variety of marine organisms, including sponges, 
tunicates, sea hare and invertebrates such as proferia and cnidaria.23 Dolastatins (8) are compounds 
derived from cyanobacterium and are currently undergoing trials for the treatment of melanoma.23 
A broad-spectrum cancer drug, trabectedin (9), is derived from the tunicate, Ecteinascidia 
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turbinata. This drug interacts with the minor grooves of DNA and interferes with transcription, 
repair mechanisms, and cellular division.23 A synthetic analog of phenylahisitin, Plinabulin (10), 
is derived from the marine fungus, Aspergillus, and impedes tumor growth via the inhibition of 
tubulin polymerization, inducing apoptosis, and disrupting the vasculature of the tumor.23 These 
three compounds are illustrated in Figure 3. 
 
Figure 3 Cancer-fighting natural products derived from marine organisms 
Another family of compounds with specific interest for cancer therapy are the aurilides. 
These depsipeptides, originally derived from sea hare, and are currently being investigated for 
cancer therapy as they often have toxicity values in the picomolar to nanomolar range.24 Aurilides 
are macrocyclic compounds containing amino acids. Compounds that belong to the aurilide family 
include aurilides A, B, and C, paul’au amide, and kulokehahilide-2.25 The lagunamides are 
structurally similar to aurilides and are also categorized as depsipeptides. Structural similarities 
10 
between aurilides and lagunamides, along with their respective IC50 values, are shown in Figure 
4. 
Figure 4 Structures and IC50 values of select aurilides and lagunamides 
Secondary metabolites from marine cyanobacteria have also been proven to be of interest 
due to their unique antimalarial and anticancer properties.26 Lagunamide A (14), lagunamide B 
(15), and lagunamide C (16) are secondary metabolites that were first isolated from the 
cyanobacterium Lyngbya majuscula by Tan et al. from Palau Hantu Besar, Singapore in 2007.25 
Each compound was tested for cytotoxicity and showed impressive antimalarial and anticancer 
activities through mitochondrial-mediated apoptosis.26 Lagunamides A and B showed IC50 values 
of 0.19 µM and 0.91 µM, respectively, for antimalarial activity. Lagunamide C has shown 
11 
anticancer activity, as such by its IC50 values, towards an array of cancer cell lines including P388 
(leukemia, 24.4 nM), A549 (lung, 2.4 nM), PC3 (prostate, 2.6 nM), HCT8 (colon, 2.1 nM), and 
SK-OV3 (ovarian, 4.5 nM).25, 26 
Similar to aurilides, the lagunamides have a polypeptide backbone, composed of five 
amino acids, and a polyketide fragment. The pentapeptide backbone is very similar in lagunamides 
A, B, and C; however, each lagunamide has a unique polyketide fragment. These differences may 
be the cause of the differing toxicities associated with each lagunamide. The synthesis of 
Lagunamide A and an analog of lagunamide B have been reported and the total synthesis of 
lagunamide C and an analog of lagunamide C is currently underway.27, 28 These synthetic routes 
will be discussed in Chapter 2.  
 1.3 Summary 
Natural products are derived from many types of organisms and are useful in treating 
various conditions including neuromuscular disorders, pain, and cancer.6, 8, 9, 14, 18 Extraction of 
these compounds from their natural sources is often not ecologically nor economically feasible, 
and therefore can be produced synthetically.1, 17, 20 This method may be questioned by the scientific 
community as it is a lengthy, and often expensive, process.1, 20 Total synthesis offers benefits that 
include producing compounds not naturally produced in nature and confident structural 
elucidation. 
Cancer-fighting natural products have been extracted from marine sources.22, 23, 24, 26 Total 
synthesis has made many of these compounds available for pharmaceutical use.22, 23, 24, 26 
Lagunamides A, B, and C have shown impressive cytotoxicities towards a variety of cancel cell 
lines. The synthesis of Lagunamide A and an analog of lagunamide B have been reported and it 
was proven that the original structures produced by the isolation team were incorrect.27, 28 
12 
Lagunamide C has yet to be synthesized and its structure confidently elucidated. To be delineated 
herein are the efforts of developing a tunable route to obtain lagunamide C. 
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Chapter 2: Previous Synthesis and Proposed Work 
 2.0 Previous Synthetic Work 
The total syntheses of lagunamide A (14) and an analog of lagunamide B (15.1) have been 
reported.27, 28 Dissection of both compounds break them into a polypeptide backbone and a 
polyketide fragment (highlighted in green in Figure 5). Lagunamides A, B, and C share 
structurally similar polypeptide backbones and can be synthesized by a series of peptide couplings. 
The focus will be on the synthesis of the polyketide fragments within the compounds. The 
polyketide fragments differ in all three compounds, and it is proposed that this moiety could be 
related to the varying toxicities associated with each lagunamide. The differences within the 
polyketide moieties (shown in green) of the lagunamides are highlighted in Figure 5 in the red 
Figure 5 Polyketide fragments of lagunamides A, B, and C 
14 
15.1 
16 
14 
boxes.25, 26, 29 While lagunamide A and lagunamide C are almost structurally identical, the 
crotylation techniques employed for the synthesis of lagunamide A are not applicable in 
synthesizing the polyketide fragment of lagunamide C due to the addition of one carbon in the 
polyketide fragment of lagunamide C. This, in addition to the stereochemical inaccuracies, 
validates the necessity of a new synthetic route to obtain lagunamide C. 
 2.0.1 Synthesis of lagunamide A 
The structure of lagunamide A was elucidated by the isolation team via intense 
spectroscopic methods.27 After the total synthesis was completed, it was found that the previously 
elucidated structure was incorrect initially due to skepticism related to the “anticipated common 
bacterial biogenesis of related marine nature products.”27 The stereochemical assignment of C39 
was identified as S but proven to be R via total synthesis of diastereomers of the compound. The 
spectra of the diasteromers was compared to that of the original isolated compound and it was 
found that the C39 stereochemistry was indeed assigned incorrectly, as illustrated in Figure 6. 
 
Figure 6 Published and revised structures of lagunamide A27 
The total synthesis and stereochemical revision of lagunamide A was completed in 2012 
by Dai and coworkers.27 The compound is composed of 11 stereogenic centers, 8 of which are 
14 14.1 
15 
found within the pentapeptide backbone, as shown in Scheme 4.27 The synthesis of the polyketide 
fragment of lagunamide A features a chiral auxiliary, DIBAl-H reductive cleavage, 
diastereoselective allylation, and oxidative cleavage.  
 
Scheme 4 Retrosynthetic analysis of lagunamide A, adapted from Dai. 27 
The synthesis of the polyketide fragment of lagunamide A, illustrated in Scheme 5,  was 
initiated by treating the modified Evans (R)-oxazolidinone, (23), with (S)-2-methyl butanal to give 
the corresponding alcohol. The alcohol was subsequently converted into anisylidine acetal (24) in 
a two-step process via NaBH4 reductive elimination.
27 The diol was then subjected to 
acetinidization followed by a DIBAl-H reduction of the acetal to the primary alcohol. The 
remaining alcohol was then subjected to a Dess-Martin oxidation to afford the aldehyde that then 
underwent diastereoselective allylation via Keck’s protocol to produce homoallylic alcohols in an 
14 
17 
18 
19 = polyketide    
fragment 
20 
21 22 
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anti-syn ratio of 7:3 (25 and 26). The homoallylic alcohol was then protected via TES ether and 
subjected to an osmium tetroxide mediated oxidative cleavage, producing aldehyde 27. The 
aldehyde was then homologated via Horner-Wadsworth-Emmons condensation and the diols were 
deprotected to afford compound 19. 
Scheme 5 Synthesis of 30 adapted from Dai.27 
The stereochemistry of the homoallylic alcohol was confirmed via observation of a 
respective acetonidization of the compound. The 13C-NMR spectra of the methyl groups of the 
acetonide showed characteristics of anti-1,3-diol. To ensure the integrity of the stereochemistry 
within the diol, an alternative approach, as shown in Scheme 6, was executed in which a 
17 
homoallylic alcohol (31) was TES protected (32), subjected towards oxidative cleavage, and then 
converted into the homoallylic alcohol via reagent controlled anti-crotylation. Following 
deprotection, the 1,3 diol was reprotected via acetonizidation to produce 33. The alkene was 
hydrogenated and the resulting alcohol was oxidized to the corresponding aldehyde (34). The 
aldehyde was subjected to a Horner-Wadsworth-Emmons olefinaion with the desired phosphonate 
and the diols were deprotected. It was ultimately found that the diol’s stereochemistry remained 
unchanged and identical to 19; the deprotected form of 30 that was produced via the original 
method. 
 
Scheme 6 Alternative route towards 19 
After 19 was joined to the polypeptide backbone (17) and lagunamide A was synthesized, 
the authors noted that the synthesized structure “appeared epimeric to the proposed structure.”27 
At least two points in the macrocycle contained the incorrect configuration. Diastereomers were 
synthesized by preparing homoallylic alcohols from the common intermediate using the previous 
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protocol and 13C-NMR data of the synthesized compounds were compared to the originally 
isolated compound. This showed that while the C39 configuration was incorrect, there was another 
location, C6, within the macrocycle that required revision. The polypeptide portion was altered by 
replacing L-allo-isoleucine with L-isoleucine, and this, including the revision within the polyketide 
portion, produced the true configuration of lagunamide A, as previously shown in Figure 6.27  
This stereochemical revision also impacts the stereochemical assignments within 
lagunamides B and C.27 According to Tan and coworkers, Lagunamides A, B and C should have 
the same stereochemical assignment on C39. A total synthesis of lagunamides B and C are 
necessary to elucidate the correct structures of these compounds. 
 2.0.2 Synthesis of 15.1 
Lagunamide B is composed of 10 stereogenic centers (7 from the amino acid backbone), a 
polyketide fragment, one hydroxyl acid, two L-amino acids, and three N-methyl amino acid 
residues in a 26-membered macrocycle.28 An analog of lagunamide B (15.1), as illustrated in 
Figure 7, was synthesized by Pal and Chakraborty in 2014.28  
 
Figure 7 Structures of lagunamide B and analog of lagunamide B  
 
15 15.1 
19 
 
Scheme 7 Deconstruction of 15.1 adapted from Pal and Chakraborty27 
 As in lagunamide A, the analog of lagunamide B (15.1) can be broken down into a 
polypeptide backbone (89) and polyketide fragment (47), as shown in Scheme 7 and Scheme 8. 
The synthesis of the polyketide portion featured the use of two chiral auxiliaries and titanium-
mediated mixed aldol reactions. The synthetic route is illustrated in Scheme 8.  
As described by Pal and Chakraborty, the chiral auxiliary (35) was subjected towards a 
titanium-mediated mixed aldol reaction to produce 36 and then TBS protected to produce 37. After 
the alcohol was protected, the compound was subjected towards lithium borohydride reduction to 
afford 38 followed by oxidation to produce 39. Aldehyde 39 was then subjected towards a 
titanium-mediated mixed aldol reaction with auxiliary 40 to afford diastereomers 41 and 42. With 
42 in the desired conformation, it was subjected towards LiBH4 reduction to remove the auxiliary 
and then Piv protected to afford 43. The TBS group was then removed from 43 to produce 44. The 
diol was then protected via acetonidization to afford 45. This compound was combined with 46 to 
afford the polyketide fragment of the analog of lagunamide B (47). 
The synthesis of the analog of lagunamide B laid the framework for the synthesis of the 
target molecule, lagunamide B, and supported the conclusion that the stereocenter on C39 of 
15.1 
46 
90 
89 
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lagunamide A was misassigned. With knowledge of the misassigned stereocenter in lagunamides 
A and B, a total synthesis of lagunamide C is necessary to completely and confidently confirm the 
stereochemistry of three stereogenic centers within the polyketide fragment of the compound.  
Scheme 8 Synthetic route of polyketide 47 in 15.1 adapted from Pal and Chakraborty.28  
As mentioned previously, the polypeptide backbones of lagunamides A, B and C are 
structurally alike, and therefore, can be synthesized similarly.29 The polyketide fragment of 
lagunamide C is unique, and will require its own synthetic route. Components of the syntheses of 
35 
36
 
37
 
38 39 41 
40 
42 
43 44 45 
46 47 
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the polyketide fragments within lagunamides A and B may be employed. It is proposed that eight 
diasteromers of the polyketide fragment within lagunamide C (48-55), be produced to elucidate its 
structure correctly, as shown in Figure 8. 
Figure 8 Diastereomers of lagunamide C polyketide 
 2.1 Retrosynthetic Analysis of Lagunamide C 
The retrosynthetic analysis of the proposed structure of lagunamide C (16.1) breaks this 
natural product into three separate components: a pentapeptide backbone (56) a polyketide 
fragment (57) and commercially available methyl-D-alanine (58) as shown in Scheme 9. The 
pentapeptide backbone is composed of D-isoleucine, L-alanine, methyl-D-phenylalanine, and 
methyl glycine and can be constructed through a series of peptide couplings and deprotections. 
The retrosynthetic analysis of polyketide 57 is more intricate, as it contains three stereogenic 
centers and will require facially selective reactions to achieve the desired stereogenic centers.  
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Scheme 9 Lagunamide C deconstruction 
As shown in Scheme 10, compound 2 can be accessed via a Mukaiyama vinylous aldol 
reaction from a silyl ketene 58 and aldehyde 59. The aldehyde can be obtained via a reductive 
opening of iodimethylcyclopropane 61, which can then be accessed from 60 via its reduction to 
form an allylic alcohol. The allylic alcohol can then undergo a selective cyclopropanation and an 
iodine substitution to form 61. Compound 62 can be accessed via Wittig olefination of 63 and 
compound 63 can be accessed via mixed aldol reaction of 64 and (S)-2-methyl butanal (66). 
Auxiliary 64 can ultimately be formed from L-valine (65) and (S)-2-methyl butanal (66) can be 
obtained via oxidation of commercially available (S)-2-methyl butanol (67).30 
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Scheme 10 Retrosynthetic analysis of 57 
2.2 Proposed Work of the Polyketide Fragment 
 The synthesis of the polyketide of lagunamide C is organized into three modules. This 
modular approach allows for optimization and stereospecificity. Each module produces one of the 
three desired stereocenters in the polyketide, allowing access to all eight diastereomers of 
lagunamide C. Key steps of the proposed synthetic route include a titanium mediated mixed aldol, 
enantioselective cyclopropanation, Charette cyclopropane ring-opening, and CBS reduction.32, 36 
 2.2.1 Module I  
The first module of the synthesis involves forming the Crimmin’s auxiliary according to 
methods described by Crimmins followed by the acetylation of the auxiliary.30 The acetylated 
auxiliary (64) is then subjected towards a facially selective titanium mediated mixed aldol reaction 
as shown in the proposed route in Scheme 11.30, 31  
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Scheme 11 Module I: Forming the first stereocenter via titanium-mediated mixed aldol 
In addition to the Crimmin’s auxiliary, equivalent control of the titanium tetrachloride will 
allow for stereospecificity of the reaction. The titanium tetrachloride interacts with the thione of 
the thiozolidinone ring of the auxiliary, the desired aldehyde, and acetyl group on the acetylated 
auxiliary. The (–)-sparteine will allow for the desired chelation effect between the acetylated 
Crimmins and the titanium tetrachloride, thereby forming the anticipated Evans-syn product, as 
described by Crimmins and as shown in Scheme 12.30, 31 
 
Scheme 12 Equivalent control of TiCl4, adapted from Hodge and Olivio and Crimmins
30, 31 
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 2.2.2 Module II 
 The second module, shown in Scheme 13, will begin with a Charette cyclopropanation of 
the allylic alcohol produced in Module I. Facial selectivity is achieved by using (S)-(-)-2-methyl-
CBS-oxazaborolidine, diethyl zinc, and methylene iodide.32 The cyclopropanated material then 
will undergo a halogen exchange, followed by a ring opening olefination.32 The remaining terminal 
olefin will then be hydroxylated and oxidized to form the aldehyde, completing module II.32, 33 
Scheme 13 Module II: Stereospecific cyclopropanation via dioxaborolane catalysis32 
 2.2.3 Module III  
The aldehyde accessed from Module II will be subjected to a Mukaiyama aldol reaction 
and then to a stereoselective reduction, as illustrated in Scheme 14.33 The proposed Mukaiyama 
aldol reaction has been reported to produce single diastereomers; however, it is expected that the 
produced diastereomer would be in the opposite configuration.33 This selectivity is due to the 
interactions between the α-methyl-β-OTBS ketones. It is also proposed that the silated alcohol 
group plays a significant role in the selectivity. 33, 34, 35  
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Scheme 14 Module III: Stereoselective reduction to achieve the third stereocenter 
Due to the desired stereoselectivity and the positioning of the protected hydroxyl group, an 
achiral reducing agent, such as NaBH4, is insufficient for the reduction.
36 An enantioselective 
reduction technique developed by Corey that employs the catalyst, (S)-(-)-2-methyl-CBS-
oxazaborolidine, is used to access the proposed transition state as illustrated in Scheme 15.36 It is 
a useful strategy to achieve the desired conformation due to the interactions between the ketone 
and methylated boron, as this would allow the hydride to be added to the si face of the carbonyl.36 
The reduction of the ketone will produce the third stereocenter within the fragment, completing 
the polyketide fragment of lagunamide C. 
Scheme 15 Proposed transition state of CBS reduction as adapted from Corey and Halal.36 
 2.3 Summary 
Previous work involving the total synthesis of lagunamide A and the total synthesis of an 
analog of lagunamide B have been discussed. Due to the incorrectly assigned stereocenters within 
lagunamides A and B, it is possible that the current assigned stereocenters within lagunamide C 
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may also be incorrect. The synthetic methods used to obtain the polyketide fragments of 
lagunamides A and B are ineffective for synthesizing lagunamide C due to the addition of one 
carbon atom in the polyketide fragment of lagunamide C. This and the stereochemical inaccuracies 
prove that a new synthetic route is necessary to confidently confirm the structure of lagunamide 
C. A synthetic route that allows for the formation of all eight possible diastereomers has been 
proposed via a modular approach. Each module contains a key component in which a stereogenic 
center is formed and can be easily manipulated to achieve the desired stereochemistry. 
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Chapter 3: Current Synthetic Work 
 3.1 Introduction  
 It is envisioned that the proposed modular approach for the synthesis of lagunamide C will 
afford a stereogenic center in each separate module. This route was tested on a model system in 
which butanal (75) was used in place of (2S)-2-methyl butanal (66) in the first module, as shown 
in Scheme 16, to produce a methyl-truncated analog of the desired system.37 This model system 
appropriately tests the validity of the proposed route, specifically in the second module where the 
cyclopropanation and ring opening result in the formation of the second stereocenter. This methyl-
truncated model system has thus far proven to be suitable, as the cyclopropanation and ring 
opening were successful. 
 
 
Scheme 16 Proposed terminal alkene vs methyl-truncated terminal alkene 
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 3.2 Module I  
The first module is centered on the titanium-mediated mixed aldol reaction that results in 
the formation of a stereogenic center. This component employs a chiral auxiliary to influence the 
desired stereochemical outcome. The synthesis of the Crimmins’ Auxiliary is shown in Scheme 
17. The amino acid, L-valine (66), was subjected towards a LiAlH4  reduction to provide L-valinol 
(76). L-Valinol (76) was then formed into the Crimmins auxiliary (77) via Crimmin’s protocol in 
which two equivalents of carbon disulfide are used to ensure the formation of the 
thiazolidinethione ring instead of the oxozolidione ring. Auxiliaries are useful because they 
provide facial selectivity and can be removed with relative ease. 31 
 
Scheme 17 Formation and acetylation of Crimmins' Auxiliary 
A thiazolidinethione ring was selected for the synthesis due to the reduced nucleophilicity 
of the thione versus a ketone in the subsequent mixed aldol reaction.31 Thione auxiliaries are also 
more easily removed and recovered than oxozolidinone rings.30, 31 This, in addition to equivalent 
control, allows for favorable interactions with the base, titanium, and aldehyde during the mixed 
aldol reaction that leads to the desired conformation of the products, as discussed in the proposed 
route.31   
Following the formation of the auxiliary, it was acetylated to form 64 and subjected 
towards a titanium-mediated mixed aldol reaction and formed two separable diasteromers (73, 78). 
While the proposed route suggests using (-)-sparteine as a chiral base, NMP and LDA provided 
the same effect and produced the desired product at comparable yields through equivalent control 
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of the titanium tetrachloride and the chelation effect of the NMP and LDA. 29 Zhou and coworkers 
used a very similar procedure to obtain diasteromers 73 and 78 as was used in this work. The 
difference is the Zhou group’s use of a non-chiral base, DIPEA, in place of the LDA and NMP 
combination employed here.37 This difference may account for the stereochemical inversion 
observed with the formed products. 
 
Scheme 18 Titanium-mediated mixed aldol reaction 
The stereochemistry of 73 and 78 were confirmed by comparing the spectra to identified 
compounds by Zhou and coworkers.37 The 1H-NMR data was characterized for both diastereomers 
produced by the reaction, but there was uncertainty about the stereochemistry of each compound. 
Suggestions were made due to the interactions resulting from the equivalent control of the TiCl4 
in the mixed aldol reaction, the relative polarity of the compounds, and the amounts of each 
compound produced. It was hypothesized that the major diasteromer contained the R 
configuration. These questions were validated by comparing the spectra of the compound formed 
by Zhou and coworkers. There are distinctive peaks in the 3.5-3.2 range, highlighted in gray in 
Table 1, that indicate the similarities between the two synthesized compounds.37 The spectra of 
31 
73 is illustrated in Figure 9. Diastereomer 73 was used for the remainder of the synthesis after 
identifying its configuration.37 
 
                         
        Figure 9 Compound synthesized by Zhou Group vs. Compound 73 
 
 
 
Table 1 Proton NMR Comparison of 73 37 
No. 1H-NMR ppm- Zhou 1H-NMR ppm- Compound 73 
5 5.17 (ddd, 1H, J = 7.61, 6.42, 1.01 Hz, H-9) 5.18 (ddd, J = 7.6, 6.2, 1.2 Hz, 1H), 
13 4.03 (m, 1H, H-4) 4.03 (m, J = 8.5, 7.4 Hz, 1H), 
11,4 3.51 (dd, 1H, J = 11.6, 7.98 Hz, H-8) 3.55 – 3.41 (m, 2H) 
 3.43 (dd, 1H, J = 17.4, 9.35 Hz, H-5)  
4 3.32 (dd, 1H, J = 17.4, 2.65 Hz, H-5) 3.34 (m, J = 2.8 Hz, 1H) 
11 3.03 (dd, 1H, J = 11.6, 1.10 Hz, H-8) 3.04 (d, J = 11.5, 1.2 Hz, 1H) 
6 2.35 (ABX6, 1H, J = 6.78 Hz, H-10) 2.42 – 2.29 (m, J = 7.0 Hz, 1H) 
14,15 1.58 - 1.33 (m, 4H, H-2, H-3) 1.64 – 1.32 (m, 4H) 
7,8,16 1.05 (d, 3H, J = 6.88 Hz, H-11) 1.09 – 1.04 (d, 3H) 
 0.98 (d, 3H, J = 6.77 Hz, H-11) 0.98 (d, J = 6.9 Hz, 3H) 
 0.92 (t, 3H, J = 6.97 Hz, H-1) 0.95 – 0.90 (m, 3H). 
32 
 
Following the isolation of 73, it was TBS protected to give 79 and underwent reductive 
cleavage of the auxiliary to reveal primary alcohol 80 via NaBH4 reduction, as shown in Scheme 
19.  
 
Scheme 19 TBS protection and reductive cleavage of 73 
The remaining alcohol (80) was then oxidized via Swern oxidation to aldehyde 81. With 
81 in hand, it was subjected towards a Wittig olefination to afford ester 82. The ester (82) was then 
Figure 10 Proton NMR of 73 
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13 
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reduced via DIBAl-H reduction to afford allylic alcohol 83. The production of alcohol 83 
successfully completed Module I of the synthetic route, as shown in Scheme 20. 
 
Scheme 20 Oxidation, Wittig olefination, DIBAl-H reduction 
 3.3 Module II 
Before beginning the second module with 83, a model system using trans-2-hexenol (84) 
was initially used to confirm the effectiveness of the cyclopropanation, mesylation, and 
halogenation, as shown in Scheme 21.  
 
Scheme 21 Model system of cyclopropanation and halogenation using 2-hexenol (84) 
Several approaches were attempted before achieving a successful cyclopropanation. These 
approaches included various temperature conditions and reaction times, as outlined in Table 2. It 
was originally proposed to perform this step via facially selective dioxaborolane catalyst, but was 
completed under non-stereospecific conditions in an attempt to prove the success of the 
cyclopropanation and conserve the dioxoborolane catalyst.36, 37 The cyclopropanation proved to be 
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effective, but did not provide separable diastereomers in neither the trans-2-hexenol model system 
nor methyl truncated system. 
Reagents Temperature Conditions Outcome 
CH2I2, ZnEt2, 
TiCl4 
0 °C to -20 °C, stir 7 hours at -20 °C SM decomposition 
 0 °C to -20 °C stir 7 hours at -20 °C in 
cold room 
SM decomposition 
ZnEt2, CH2I2 -20 °C stir 7 hours in cold room Partial 
cyclopropanation 
 0 °C to RT, stir O/N Product, 95 % yield 
 
Table 2 Reaction conditions of cyclopropanation of 84 
After the successful cyclopropanation of 84, the mixture of cyclopropanated material (85) 
was then subjected towards mesylation of the primary alcohol, followed by the iodine-substitution 
(86), illustrated previously in Scheme 21. Several methods were attempted to ensure the desired 
mesylation and halogenation products were formed. These attempts involved various temperature 
conditions, reaction times, and order of reactant addition as outlined in Table 3. It was ultimately 
found that the mesylated material quickly degraded after being formed and that direct halogenation 
of the crude mesylated material was necessary to achieve the desired iodine-substituted product. 
Reagents  Reaction Conditions Outcome 
1.) MsCl, triethylamine in DCM 
2.) NaI in acetone 
1.) 0 °C 
2.) RT 
Low yields 
<10% 
 Allowed NaI to stir O/N before 
workup and purification 
SM decomposition 
1.) MsCl, triethylamine, THF 
2.) NaI, THF 
1.) 0°C 
2.) RT 
Low yields 
<10% 
 Allowed NaI to stir O/N before 
workup and purification 
SM decomposition 
1.) MsCl, triethylamine, DCM 
2.) NaI in acetone 
Completed full workup before 
subjecting towards second 
reaction 
SM decomposition 
 Completed full workup and 
purification before subjecting 
towards second reaction 
SM decomposition 
 Allowed NaI to stir O/N before 
workup and purification 
SM decomposition 
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Table 3 Halogenation reaction conditions completed with 85 
Once the model system had proven to be successful, these methods were applied to the 
desired system and successfully resulted in the iodine-substituted cyclopropanated material, 88, as 
shown in Scheme 22. 
 
Scheme 22 Cyclopropanation, iodine substitution of 83 
The iodine-substituted compound (88) then underwent lithium-halogen exchange, 
followed by a Charette cyclopropane ring-opening, to afford the desired terminal alkene 74 in 55% 
yield. This step produced two separable diastereomers and is shown in Scheme 23. The successful 
formation of terminal alkene 74 shows that the proposed route is effective and can be applied 
towards the synthesis of lagunamide C. 
 
Scheme 23 Charette ring-opening of 88 32 
Table 3 Continued   
Reagents Reaction Conditions Outcome 
1.) MsCl, triethylamine, DCM 
2.) NaI in acetone 
 
 
Removed DCM after stirring for 
approximately 45 minutes at 0 
°C before subjecting to second 
reaction 
Low yields 
<10% 
1.) Triethylamine, MsCl, DCM 
2.) NaI in acetone 
Changed order of addition in 
mesylation, 0 °C, DCM 
removed after approximately 45 
min., continued immediately 
with second reaction 
Worked, higher 
yields 
>60%, Selected as 
appropriate 
procedure 
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 3.4 Summary 
 Module I and the key steps of module II have been successfully completed with a methyl-
truncated system. The truncated system was employed in order to more rapidly and economically 
test the suggested route of obtaining the polyketide fragment. The truncated system also allowed 
for the formation of possible analogs to be subjected towards future cytotoxicity screenings. While 
the chiral base (-)-sparteine was substituted for NMP and LDA during the titanium-mediated 
mixed aldol reaction, separable diasteromers were produced to afford the first stereogenic center 
within the polyketide fragment. The configurations of the diasteromers were confirmed and the 
desired configuration was continued in the synthetic route.  
 The key steps of module II, the cyclopropanation and ring opening, were initially tested 
using a model system with trans-2-hexenol. Once the reaction conditions using the model system 
were optimized successfully via non-facially selective methods, they were applied towards the 
desired system to produce the terminal alkene. The cyclopropanation produced two diastereomers 
that were later separated following the Charette ring-opening reaction. The ring opening of the 
cyclopropane reveals the second stereogenic center of the polyketide, thereby accessing two of the 
three questionable stereogenic centers within the polyketide fragment. Completing these key steps 
validates the current synthetic route and can be applied towards the target system to synthesize 
lagunamide C. 
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Chapter 4: Conclusion and future work 
 4.1 Conclusion 
Total synthesis is a relatively economic and ecological method of obtaining biologically 
active compounds derived from natural products when compared to extraction.1, 20 This method 
has been applied to obtain a plethora of drugs used to treat a multitude of conditions including 
various types of cancer, pain, strabismus, and hyperactive sweating. 8, 9, 14, 16, 23 Many of these 
fascinating compounds are derived from secondary metabolites and often used by organisms as 
defense mechanisms.6, 24, 26 While terrestrial sources have produced many useful natural products, 
the earth’s oceans are also an invaluable source for new synthetically interesting and bioactive 
compounds.22, 23, 26, 29 
The bioactive compound lagunamide C has yet to be synthesized. There is dispute towards 
the assignment of three stereocenters within the polyketide portion of the compound. A selective, 
modular approach has been proposed to synthesize the polyketide fragment within this compound 
and confidently assign the unknown stereocenters. This approach has first been applied towards a 
methyl-truncated analog of lagunamide C, which will lay the foundation for the synthesis of the 
polyketide fragment of lagunamide C and potential future analogs. 
The final stages of achieving a scalable, synthetic pathway for a methyl truncated analog 
of lagunamide C are underway by using the proposed modular approach. The current synthetic 
route has proven to be scalable. The synthetic route suggested the use of chiral catalysts to achieve 
the ideal stereochemistry of the compounds. Non-selective methods have been used initially to 
ensure the formation of the product and have been useful for possible analog studies. It has also 
been found that the diasteromers produced in the non-selective steps are separable via column 
chromatography. 
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The stereochemistry has been confirmed for the stereogenic center produced in Module 1 
by comparing spectral data to previously synthesized compounds.37 The key components of the 
proposed route, the cyclopropanation and Charette cyclopropane ring-opening have been effective, 
thus validating the proposed route. These techniques will be later applied towards synthesizing 
lagunamide C. 
 4.2 Future work 
Future work will include applying this established synthetic route to accomplish the total 
synthesis of the of lagunamide C. Components of the current synthetic route may be altered to 
achieve higher selectivity at the titanium-mediated mixed aldol stage, as the current methods allow 
for some selectivity. This could be adjusted to produce the desired stereocenter at higher yields by 
using a more sterically hindering auxiliary to influence the stereo-selectivity in the reaction or 
using (-)-sparteine as suggested in the proposed route. 
 In Module II, a dioxaborolane catalyst is suggested to promote stereoselectivity towards 
the cyclopropanation; however, the diastereomers are separable following the ring-opening of the 
cyclopropane ring.32 For the purpose of producing analogs, it may be favorable to consider not 
using the catalyst and move forward with the synthetic route with the separated compounds. 
Following the completion of Module II, the route will be applied towards the synthesis of 
lagunamide C. The synthesis of the pentapeptide backbone is currently underway and will be 
joined with the prepared polyketide fragment once synthesis of the fragment is completed. 
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Chapter 5: Experimental Procedures 
Experimental Details: Reactions completed with anhydrous protocol were completed in flame-
dried glassware under argon. Dry solvents were obtained directly from a solvent system. All 
products were dried with anhydrous sodium sulfate as part of the workup. Compounds were 
purified via flash-silica chromatography with specified solvent systems, unless otherwise noted. 
1H-NMR and 13C-NMR data were obtained from a Varian 400 MHz at Kansas State University. 
High-resolution mass spectra were obtained using a LCT Premier Time of Flight mass 
spectrometer at the University of Kansas. 
 L-Valinol 
 
In a dry, round bottom flask, LiAlH4 (1.88g, 51 mmol, 3 eq.) and THF (0.24 M) were 
combined and cooled to 0 °C. L-valine, 66, (2.00g, 17 mmol, 1 eq.) was added slowly while 
stirring.  The ice bath was removed and the mixture was warmed to room temperature. The solution 
was then refluxed overnight at 70 °C. The solution was diluted with ether and cooled to 0 °C. The 
LiAlH4 was quenched with H2O and 15% NaOH, forming a white precipitate. The solution was 
decanted into another flask and the precipitate was rinsed with ether. The liquid was added to the 
solution and the white precipitate was disposed. Alternatively, saturated Rochelle salt solution can 
be added to the flask and stirred overnight. The aqueous layer can then be extracted with CH2Cl2 
(x3), and the resulting organic layers dried and concentrated to afford an oily, crude product. The 
crude product was purified via short path vacuum distillation resulting in obtaining 76 (1.00 g, 57 
%). 
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1H-NMR (400 MHz, Chloroform-d): δ 3.63 (dd, J = 10.4, 4.0 Hz, 1H), 3.27 (dd, J = 10.4, 8.9 
Hz, 1H), 2.54 (m, J = 8.9, 6.4, 4.0 Hz, 1H), 1.54 (m, J = 13.5, 6.7 Hz, 1H), 0.92 (d, J = 6.1 Hz, 
3H), 0.90 (d, J = 6.1 Hz, 3H). 
Notebook: CH1-045 
 
 
0.91 (d, 3H) 
0.90 (d, 3H) 
 
1.55 (m, 1H) 
3H 3.63 (dd, 1H) 
3.27 (dd, 1H) 
 
Key 1H-NMR Peaks of L-Valinol 
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 (S)-4-isopropylthiazolidine-2-thione 
 
L-valinol, 76, (10.00 g, 96.7 mmol, 1 eq.), CS2 (15.2 mL, 251.8 mmol, 2.6 eq.), and EtOH 
(29.3 mL, 3.3 M) were combined in a round bottom flask. An addition funnel was attached to the 
flask, flushed with argon, and charged with 2.25M KOH (116.3 mL, 261.6 mmol, 2.25 M). The 
KOH was slowly added to the flask with stirring. After the KOH was added, the addition funnel 
was replaced with a condensing tube and flushed with argon. The solution was left to reflux at 80 
°C for 72 hours. Over the course of the reflux period, the solution changed from bright orange to 
light yellow. The flask was then cooled to room temperature and volatiles were removed under 
reduced pressure. The solution was acidified with 1 M HCl and then extracted with CH2Cl2 (x3). 
The combined organic layers were then dried and concentrated under reduced pressure, producing 
a light yellow solid. The crude product, 77 (15.04 g, 96 %), was used for subsequent reactions 
without further purification  
 
 
 
 
 
 
 
 
1H-NMR (400 MHz, Chloroform-d): δ 8.40 (s, 1H), 4.09 – 4.02 (q, 1H), 3.49 (dd, J = 11.2, 8.3 
Hz, 1H), 3.30 (dd, J = 11.2, 8.2 Hz, 2H), 2.05 – 1.86 (m, J = 6.7 Hz, 1H), 1.01 (d, J = 6.8 Hz, 
3H), 0.98 (d, J = 6.8 Hz, 3H). 
 
Key 1H-NMR Peaks of (S)-4-isopropylthiazolidine-2-thione 
 
1.01 (d, 3H) 
0.98 (d, 3H) 
 
4.09-4.02 (m, 1H) 
2.05-1.86 (m, 1H) 
8.40 (s, 1H) 
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HRMS: calculated for [C6H11NS2 + H
+] 162.0406, found 162.0402. 
Notebook: CH1-401 
 
 
 (S)-1-(4-isopropyl-2-thioxothiazolidin-3-yl)ethan-1-one 
 
A dry round bottom flask was charged with crude 77 (2.00 g, 12.4 mmol, 1 eq.) and dry 
THF (8.26 mL, 1.5 M). The solution was cooled to -83 °C via ethyl acetate-dry ice bath and then 
1.6 M n-BuLi (8.53 mL, 13.64 mmol, 1.1 eq.) was added dropwise. A color changed of light 
yellow, to orange, to bright yellow was observed throughout the addition of the n-BuLi. 
Approximately 20 minutes later, acetyl chloride (1.15 mL, 16.12 mmol, 1.3 eq.) was added 
dropwise and 20 minutes afterward, the solution was warmed to room temperature. The reaction 
43 
was quenched with NH4Cl saturated solution and water, extracted with CH2Cl2 (x3), dried, and 
concentrated under reduced pressure. Flash silica chromatography (2:1 CH2Cl2/ Hexane) afforded 
64 (2.40 g, 95%).  
 
 
 
 
 
 
 
 
1H-NMR (400 MHz, Chloroform-d): δ 5.14 (m, J = 7.6, 6.2, 1.2 Hz, 1H), 3.50 (dd, J = 11.5, 
8.0 Hz, 1H), 3.02 (dd J = 11.5, 1.2 Hz, 1H), 2.77 (s, 3H), 2.36 (m, J = 13.4, 6.8 Hz, 1H), 1.06 (d, 
J = 6.8 Hz, 3H), 0.97 (d, J = 6.9 Hz, 3H).  
 
13C-NMR (101 MHz, Chloroform-d):  δ 203.42, 71.48, 30.99, 30.63, 27.14, 19.27, 17.97. 
Notebook: CH1-239 
 
Key 1H-NMR and 13C-NMR Peaks of (S)-1-(4-isopropyl-2-thioxothiazolidin-3-yl)ethan-1-one 
 
2.77 (s, 3H) 
1.06 (d, 3H) 
0.97 (d, 3H) 2.36 (m, 1H) 
5.15 (m, 1H) 
71.48 
30.99 
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 (R)-3-hydroxy-1-((S)-4-isopropyl-2-thioxothiazolidin-3-yl)hexan-1-one 
 
A dry round bottom flask was charged with 64 (1.06 g, 5.21 mmol, 1 eq.) and CH2Cl2 
(10.42 mL, 0.5 M). The contents were cooled to 0 °C. TiCl4 (0.60 mL, 5.47 mmol, 1.05 eq.) was 
added dropwise, changing the solution from a bright yellow to a bright orange color. Meanwhile, 
0.62 M LDA was prepared by adding 2.58 mL of diisopropylamine in 18.0 mL of THF and adding 
11.88 mL n-BuLi (1.6 M in hexanes) at -78 °C. Approximately 20 minutes after adding the TiCl4, 
the freshly prepared 0.62 M LDA (10.10 mL, 6.25 mmol, 1.2 eq.) was added to the solution, 
changing the color from bright orange into a deep burgundy. NMP (0.60 mL, 6.25 mmol, 1.2 eq.) 
was added approximately 20 minutes later. The solution was cooled to -78 °C and then 10 minutes 
45 
later, the butanal (0.63 mL, 7.82 mmol, 1.5 eq.) in CH2Cl2 (1.45 mL, 5.4 M) was added. Thirty 
minutes following the addition of the aldehyde, the solution was warmed from -78 °C to 0 °C with 
an ice bath. It was quenched with NH4Cl, diluted with brine, and extracted with CH2Cl2 (x4). The 
combined organic layers were then dried and concentrated under reduced pressure. Flash silica 
chromatography (2:1 hexanes/ ethyl acetate) afforded the product, composed of 2 diastereomers, 
73 (380 mg) and 78 (238 mg) and a mixture of 73 and 78 (439 mg) with an overall yield of 74%. 
Key 1H-NMR and 13C-NMR Peaks of (R)-3-hydroxy-1-((S)-4-isopropyl-2-thioxothiazolidin-3-
yl)hexan-1-one 
 
 
 
 
 
 
 
1H NMR (400 MHz, Chloroform-d): δ 5.18 (ddd, J = 7.6, 6.2, 1.2 Hz, 1H), 4.03 (m, J = 8.5, 
7.4 Hz, 1), 3.55 – 3.41 (m, 1H), 3.34 (m, J = 2.8 Hz, 1H), 3.04 (d, J = 11.5, 1.2 Hz, 1H), 2.42 – 
2.29 (m, J = 7.0 Hz, 1H), 1.64 – 1.32 (m, 4H), 1.09 – 1.04 (d, 3H), 0.98 (d, J = 6.9 Hz, 3H), 0.95 
– 0.90 (d, 3H). 
 
13C NMR (101 MHz, Chloroform-d): δ 174.03, 71.57, 68.43, 45.37, 38.97, 30.99, 30.80, 19.31, 
18.90, 18.04, 14.23. 
 
HRMS: calculated for [C12H21NS2O2 + Na
+] 298.0906, found 298.0907. 
Notebook: CH2-070 
 
 
 
 
 
 
68.43  
4.03 (m, 1H) 
5.18 (ddd, 1H) 
71.57  
3.55-3.41 (m, 1H) 
3.04 (d, 1H) 
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(R)-3-((tert-butyldimethylsilyl)oxy)-1-((S)-4-isopropyl-2-thioxothiazolidin-3-yl)hexanone 
  
A dry round bottom flask was charged with 73 (900.0 mg, 3.27 mmol), DMF (13.6 mL, 
0.24 M), TBSCl (1.97 g, 13.08 mmol, 4 eq.), and 2,6-lutidine (1.90 mL, 16.35 mmol, 5 eq.). The 
solution was stirred overnight at 33 °C under argon. To quench, the solution was diluted with ethyl 
acetate and extracted H2O (x6), brine (x1), dried, and concentrated. The crude, yellow compound 
was purified via flash silica chromatography (20:1 hexane/ethyl acetate) to produce 79 (1.29 g, 86 
%).  
 
 
 
   
 
 
 
 
 
 
1H NMR (400 MHz, Chloroform-d): δ 5.15 – 5.11 (t, 1H), 4.26 (p, J = 5.8 Hz, 1H), 3.56 – 3.44 
(m, 2H), 3.38 (dd, J = 16.8, 6.3 Hz, 1H), 3.01 (d, J = 11.5, 1.1 Hz, 1H), 2.37 (m, J = 13.5, 6.8 
Hz, 1H), 1.50 – 1.41 (m, 3H), 1.36 (m, J = 15.8, 8.0, 5.8 Hz, 3H), 1.05 (d, J = 6.8 Hz, 3H), 0.97 
(d, J = 6.9 Hz, 3H), 0.90 (t, J = 7.2 Hz, 3H), 0.87 (s, 9H), 0.06 (s, 3H), 0.05 (s, 3H). 
 
13C NMR (101 MHz, Chloroform-d): δ 71.85, 68.99, 46.20, 40.11, 31.08, 30.38, 26.06, 25.92, 
19.33, 18.49, 17.84, 14.45, -4.40. 
 
Key 1H-NMR and 13C-NMR Peaks of  
(R)-3-((tert-butyldimethylsilyl)oxy)-1-((S)-4-isopropyl-2-thioxothiazolidin-3-yl)hexanone 
 
0.87 (s, 9H) 
0.06 (s, 3H) 
0.05 (s, 3H) 
4.26 (p, 1H) 
5.15-5.11 (t, 1H) 
46.20  
68.99  
71.85  
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HRMS: calculated for [C18H35NO2S2Si + Na
+] 412.6772, found 412.6773. 
Notebook: CH2-108 
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  (R)-3-((tert-butyldimethylsilyl)oxy)hexanol 
 
A round bottom flask was charged with 79, (1.76 g, 4.50 mmol, 1 eq.), EtOH (26.47 mL, 
0.17 M), and NaBH4 (681 mg, 18 mmol, 4 eq.). The solution was stirred for approximately 4 hours. 
The bright yellow color of the starting material disappears as the reaction proceeds. To quench, a 
saturated solution of NH4Cl is added slowly to neutralize the solution. The solution is extracted 
with CH2Cl2 (x3), brine (x1), dried, and concentrated under reduced pressure. Water may also be 
added during the extraction to dissolve any of the salts remaining in solution. The crude, clear oil 
is purified via flash silica chromatography (5:1 ethyl acetate/ hexane) to afford a clear oil, the 
desired alcohol, 80 (1.05 g, 91% yield), and white solid, 77 (725.76 g, 85%).  
 
 
 
 
 
 
 
 
1H NMR (400 MHz, Chloroform-d): δ 3.91 – 3.84 (m, 1H), 3.77 (m, J = 10.7, 8.0, 4.8 Hz, 1H), 
3.66 (m, J = 10.9, 5.5 Hz, 1H), 2.73 (s, 1H), 1.82 – 1.71 (m, 1H), 1.64 – 1.55 (m, 1H), 1.50 – 
1.41 (m, 2H), 1.33 – 1.21 (m, 2H), 0.88 (t, J = 7.3 Hz, 9H), 0.86 (s, 3H), 0.05 (s, 3H) 0.04 (s, 
3H).  
 
13C NMR (101 MHz, Chloroform-d): 71.99, 60.51, 39.29, 37.88, 26.05, 18.82, 18.19, 14.46, -
4.22, -4.49. 
Key 1H-NMR and 13C-NMR Peaks for (R)-3-((tert-butyldimethylsilyl)oxy)hexanol 
 
3.91-3.84 (m, 1H) 
3.66 (m, 1H) 
 1.50-1.41 (m, 2H) 
1.81-1.71 (m, 1H) 
1.64-1.55 (m, 1H) 
 
60.51 
71.99 
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HRMS: calculated for [C19H34O2Si + Na
+] 345.2226, found 345.2213. 
Notebook: CH1-393 
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  (R)-3-((tert-butyldimethylsilyl)oxy)hexanal 
 
To a dry round bottom flask was added oxalyl chloride (0.25 mL, 2.83 mmol, 1 eq.) and 
CH2Cl2 (5.66 mL, 0.5 M). The solution was cooled to -78°C. DMSO (0.40 mL, 5.59 mmol, 2.2 
eq.) was slowly added to the solution. Approximately 15 minutes later, 80 (597.5 mg, 2.57 mmol, 
1 eq.) in CH2Cl2 (2.28 mL, 1.125 M) was added and stirred. Triethylamine (1.78 mL, 12.85 mmol, 
5 eq.) was added 1 hour later. The flask was then removed from the ice bath and warmed to room 
temperature. The solution was quenched with water and extracted with CH2Cl2 (x3). The collected 
organic layers were washed once with 2% HCl solution and once with 5% Na2CO3 solution. The 
organic layers were then dried and concentrated under reduced pressure. The reaction produced 
the crude aldehyde, 81 (1.37 g) and was used immediately for the subsequent reaction. 
 
 
 
 
 
 
 
1H NMR (400 MHz, Chloroform-d): δ 9.81 (t, J = 2.5 Hz, 1H), 4.18 (p, J = 5.9 Hz, 1H), 2.51 
(dd, J = 5.7, 2.5 Hz, 2H), 1.58 – 1.44 (m, 3H), 1.42 – 1.26 (m, 3H), 0.94 – 0.89 (t, 3H), 0.87 (s, 
9H), 0.07 (s, 3H), 0.05 (s, 3H). 
 
Notebook: CH2-144 
9.81 (t, 1H) 4.18 (p, 1H) 
Key 1H-NMR Peaks for (R)-3-((tert-butyldimethylsilyl)oxy)hexanal 
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 Methyl (R,E)-5-((tert-butyldimethylsilyl)oxy)oct-2-enoate 
 
To a dry round bottom flask was added the activated Witting reagent (1.05 g, 3.15 mmol, 
1.5 eq.) and dry toluene (6.30 mL, 0.5 M) and stirred vigorously. Meanwhile, to another dry round 
bottom flask was added 81 (483.17 mg, 2.10 mmol, 1 eq.) in dry toluene (2.63 mL, 0.8 M). The 
contents of the flasks were combined and stirred under argon overnight at room temperature. To 
quench, the solution was diluted with water and extracted with ether (x3) and brine (x1). The 
compound was then dried and concentrated under reduced pressure. The crude oil was purified via 
flash silica chromatography (5:1 ethyl acetate/hexane) affording 82 (500.0 mg, 83%) as a clear, 
colorless oil. 
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1H NMR (400 MHz, Chloroform-d): δ 6.97 (m, J = 15.3, 7.5 Hz, 1H), 5.84 (d, J = 15.7, 1.6 Hz, 
1H), 3.83 – 3.75 (m, 1H), 3.73 (s, 3H), 2.38 – 2.27 (m, 2H), 1.45 – 1.25 (m, 5H), 0.90 (m, J = 7.2 
Hz, 3H), 0.88 (s, J = 0.7 Hz, 9H), 0.04 (s, 6H).  
 
13C NMR (101 MHz, Chloroform-d): δ 146.60, 123.00, 71.28, 51.61, 40.46, 39.69, 26.05, 
18.78, 14.39. 
 
HRMS: calculated for [C15H30O3Si + Na
+] 309.1856, found 309.1860. 
Notebook: CH2-057 
3.73 (s, 3H) 
6.97 (m, 1H) 
3.83-3.75 (m, 1H) 
5.84 (d, 1H) 
39.69 
51.61 
146.60 
123.00 
Key 1H-NMR and 13C-NMR Peaks for methyl (R,E)-5-((tert-butyldimethylsilyl)oxy)oct-2-enoate 
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  (R,E)-5-((tert-butyldimethylsilyl)oxy)oct-2-en-1-ol 
 
To a flame-dried round bottom flask was added 82 (374.8 mg, 1.31 mmol, 1 eq.) and dry 
CH2Cl2 ( 6.5 mL, 0.2 M). The solution was cooled to -78°C and DIBAL-H (1 M) (3.28 mL, 3.28 
mmol, 2.5 eq.) was added. The solution was stirred until TLC analysis showed no remaining 
starting material (approximately 10-15 minutes). The solution was quenched with saturated 
Rochelle Salt solution and stirred overnight. The solution was extracted with CH2Cl2 (x3), washed 
with brine (x1), dried, and concentrated. The crude oil was purified via flash silica chromatography 
(5:1 ethyl acetate/ hexane), affording 83 (310.96 mg, 92 %) as a clear oil.  
          
 
 
 
 
 
 
 
 
1H NMR (400 MHz, Chloroform-d): δ 5.76 – 5.59 (m, 2H), 4.10 (d, J = 4.8 Hz, 2H), 3.68 (m, J 
= 5.6 Hz, 1H), 2.20 (q, J = 6.0 Hz, 2H), 1.45 – 1.21 (m, 7H), 0.90 (t, J = 6.9 Hz, 3H), 0.88 (s, J = 
0.9 Hz, 9H), 0.04 (s, 6H). 
 
13C NMR (101 MHz, Chloroform-d): δ 131.33, 129.87, 72.04, 64.02, 40.47, 39.39, 26.10, 
18.85, 18.37, 14.46, -4.16, -4.31. 
 
HRMS: calculated for [C14H30O2Si + H
+] 259.4845, found 259.4840. 
Notebook: CH2-047 
Key 1H-NMR and 13C-NMR Peaks for (R,E)-5-((tert-butyldimethylsilyl)oxy)oct-2-en-1-ol 
 
5.76-5.59 (m, 2H) 
3.68 (m, 1H) 
4.10 (d, 2H) 
40.47 
64.02 
131.33 
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  (2-((R)-2-((tert-butyldimethylsilyl)oxy)pentyl)cyclopropyl)methanol 
 
To a flame dried round bottom flask was added 83 (257.1 mg, 0.99 mmol, 1 eq.) and 
CH2Cl2 (3.0 mL, 0.33 M) and was cooled to 0°C. To another dry round bottom flask was added 
diiodomethane (0.24 mL, 3.95 mmol, 2.5 eq.) and CH2Cl2 (23 mL, 0.17 M) and was cooled to 0°C. 
To each flask was added 1 M diethyl zinc solution (1.58 mL, 1.58 mmol, 1.5 eq.). The solutions 
in each flask were stirred at 0 °C for approximately 45 minutes and then combined. The remaining 
solution was slowly warmed to room temperature and stirred overnight under an inert atmosphere. 
The reaction was quenched by adding saturated ammonium chloride and 1 M HCl solution. It was 
then extracted with CH2Cl2 (x3), brine (x1), dried, and concentrated under reduced pressure. The 
crude material was purified via flash silica chromatography (4:1 hexane/ethyl acetate) affording 
87 (256.28 mg, 95 %). 
 
 
 
 
 
 
 
 
 
 
0.43-0.28 (m, 2H) 
3.72 (m, 1H) 
3.54-3.36 (m, 2H) 
Key 1H-NMR and 13C-NMR Peaks for 
(2-((R)-2-((tert butyldimethylsilyl)oxy)pentyl)cyclopropyl)methanol 
67.43 
10.23 
72.73 
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1H NMR (400 MHz, Chloroform-d): δ 3.72 (m, J = 11.8, 5.8 Hz, 1H), 3.54 – 3.36 (m, 2H), 
1.53 (s, 1H), 1.52 – 1.43 (m, 3H), 1.39 – 1.23 (m, 3H), 0.93 – 0.89 (t, 3H), 0.89 (s, 9H), 0.73 – 
0.61 (m, 1H), 0.43 – 0.28 (m, 2H), 0.05 (s, 3H), 0.04 (s, 3H). 
 
13C NMR (101 MHz, Chloroform-d): δ 72.73, 72.43, 67.43, 41.28, 41.05, 39.56, 39.35, 26.14, 
21.55, 18.83, 14.54, 13.74, 13.49, 10.23, 10.00, -4.18. 
 
HRMS: calculated for [C15H32O2Si + Na
+] 295.4932, found 295.4934. 
Notebook: CH2-048 
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 Tert-butyl(((2R)-1-(2-(iodomethyl)cyclopropyl)pentan-2-yl)oxy)dimethylsilane 
 
To a dry round bottom flask was added 87 (730.0 mg, 2.68 mmol, 1 eq.), CH2Cl2 (17.8 mL, 
0.15 M), triethylamine (0.62 mL, 8.04 mmol, 3 eq.), and methylsulfonyl chloride (0.56 mL, 4.02 
mmol, 1.5 eq.) at 0°C. The solution was stirred for approximately 10 minutes before warming to 
room temperature and stirring for an additional 25 minutes. The solvent was then removed under 
reduced pressure, resulting in a yellow solid. To the solid was added dry acetone (17.8 mL, 0.15 
M) and NaI (3.62 g, 24.12 mmol, 9 eq). The solution was stirred for 1 hour at room temperature 
under argon. The reaction was quenched with saturated sodium bicarbonate solution and saturated 
sodium thiosulfate solution, washed with ether (x3), washed with brine (x1), dried, and 
60 
concentrated under reduced pressure. The crude product was purified via flash silica 
chromatography ( 4:1 hexane/ ethyl acetate) affording 88 (910.0 mg, 80 %) as a clear oil, composed 
of two diastereomers. 
 
 
 
 
 
 
 
 
 
1H NMR (400 MHz, Chloroform-d): δ 3.71 (m, J = 5.7 Hz, 1H), 3.29 – 3.01 (m, 2H), 1.56 – 
1.25 (m, 8H), 1.06 (m, J = 8.0, 3.8 Hz, 1H), 0.92 (t, J = 1.2 Hz, 3H), 0.90 (s, 9H), 0.79 – 0.70 (m, 
1H), 0.65 – 0.58 (m, 1H), 0.46 (m, J = 9.1, 4.7 Hz, 1H), 0.05 (s, 3H), 0.04 (s, 3H) 
 
13C NMR (101 MHz, Chloroform-d): δ 72.36, 72.12, 41.73, 41.68, 39.57, 39.43, 26.15, 23.70, 
23.39, 22.38, 22.12, 18.79, 18.35, 18.23, 18.14, 14.58, 14.01, -4.15, -4.24. 
 
Notebook: CH2-142 
3.71 (p, 1H) 
0.79-0.70 (m, 1H) 
0.65-0.58 (m, 1H) 
3.29-3.01 (m, 2H) 
Key 1H-NMR and 13C-NMR Peaks of tert-butyl(((2R)-1-(2-(iodomethyl)cyclopropyl)pentan-2-
yl)oxy)dimethylsilane 
72.36 
72.12 
14.01 
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 Tert-butyldimethyl(((4R)-6-methyloct-7-en-4-yl)oxy)silane 
 
To a dry round bottom flask was added 88 (250.3 mg, 0.65 mmol, 1 eq.), TMEDA (0.20 
mL, 1.3 mmol, 2 eq.), and 1.6M n-BuLi (0.81mL, 1.3 mmol, 2 eq.) in dry ether (3.61 mL, 0.18 M) 
at -78°C. After stirring for approximately 20 minutes, the solution was warmed to -30°C. The 
reaction was quenched with water after stirring for approximately 3.5 hours. It was then extracted 
with ether (x3), 10% HCl (x1), saturated sodium carbonate (x1), and brine (x1), dried, and 
concentrated under reduced pressure. The crude product was purified via flash silica 
chromatography (10:1 hexane/CH2Cl2) producing 74 (166 mg, 55%). 
 
 
 
 
 
 
 
 
 
1H NMR (400 MHz, Chloroform-d): δ 5.86 – 5.63 (m, 1H), 5.04 – 4.87 (m, 2H), 3.67 (m, J = 
15.0, 10.1, 5.5 Hz, 1H), 2.24 (m, J = 14.3, 7.2 Hz, 1H), 2.03 (m, J = 6.9 Hz, 1H), 1.48 – 1.30 (m, 
3H), 0.98 (d, J = 6.7, 2.8 Hz, 3H), 0.90 (t, J = 3.6 Hz, 3H), 0.88 (s, J = 0.8 Hz, 9H), 0.04 (s, 6H). 
 
13C NMR (101 MHz, Chloroform-d): δ 139.23, 114.50, 112.50, 112.46, 72.20, 44.47, 39.65 (d, 
J = 7.2 Hz), 34.47, 24.80, 20.52, 18.47, 14.55, -4.06. 
 
HRMS: calculated for [C15H32OSi + Na
+] 279.4942, found 279.4939. 
Notebook: CH2-082 
5.04-4.84 (m, 2H) 
5.87-5.61 (m, 1H) 
1.45-1.26 (m, 3H) 
3.67 (m, 1H) 
 
 
 
 
 
 
 
 
 
 
 
 
Key 1H-NMR and 13C-NMR Peaks for tert-butyldimethyl(((4R)-6-methyloct-7-en-4-yl)oxy)silane 
72.20 
39.65 
14.55 
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